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Abstract
Introduction: Breast cancer (BC) is an important public health problem worldwide. In Brazil, breast cancer is the
most frequently diagnosed tumor and the leading cause of cancer death in women. Hereditary cancer represents
approximately 5 to 10 % of BC cases. Even outside the hereditary cancer context, the presence of polymorphisms
acting as genetic modifiers may contribute to a better or worse prognosis. Not much is known about the
hereditary BC epidemiology in Brazil or about the influence of polymorphisms on hereditary predisposition.
Objective: This study examined the role of five different polymorphisms in four groups of women with BC: Group
1: women with a germline mutation in the BRCA1/2 genes; Group 2: women with variants of uncertain significance
in BRCA1/2 and Group 3: women with no mutations in BRCA1/2.
Patients and methods: The women included in groups 1, 2 and 3 were patients from the Department of
Oncogenetics of the Barretos Cancer Hospital who had undergone genetic testing because of a clinical suspicion of
hereditary predisposition syndrome. The constitutive DNA was analyzed for the presence of polymorphisms at
rs2981582 (FGFR2 gene); rs3803662 (TNRC9); rs889312 (MAP3K1); rs3817198 (LSP1 gene); and rs13281615 (8q24). The
analyses were performed using PCR amplification and bi-directional sequencing.
Results: No differences were identified in the frequency of the polymorphisms that were analyzed among the
three groups. However, some associations were identified, such as the occurrence of bilateral breast cancer and
homozygosity for the G allele in rs13281615 as well as the correlation between the SNPs rs2981582 and rs13281615
and the number of cancer cases in the family. Regarding the G allele of rs13281615, we observed that the
proportion of individuals who were homozygous for this allele increased with the number of generations affected
by cancer, regardless of the group where the patients were included. Concerning the rs2981582 we could observe
that individuals from group 1 and homozygous CC had fewer cancer (and also fewer breast cancer) cases.
Regarding the hormone receptors, we observed an increased frequency in C homozygotes (rs3803662) among
estrogen receptor-negative individuals from groups 1 and 3. For rs2981582 (FGFR2), we observed an increased
frequency of the T allele in women who were positive for the estrogen and progesterone receptors regardless of
the BRCA1/2 mutational status (p = 0.020 and p = 0.014, respectively).
Conclusion: The results presented here provide interesting data on the modifying effect of polymorphisms on a
family history of cancer; this may be a variable to consider in the analysis of tumor diversity, and of the family history
observed in families with hereditary breast cancer (even in those harboring the same type of genetic alteration).
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Introduction
In Brazil, breast neoplasms are the main cause of death
by cancer among women [1]. It is currently estimated
that 5-10 % of the total number of breast cancer (BC)
cases are hereditary. BRCA1 and BRCA2 are among the
genes associated with hereditary breast cancer [2–4].
Women harboring a germline mutation in the BRCA1
gene show a lifetime cumulative risk (LCR) between 44
and 68 % of developing breast cancer until 70 years of
age. Moreover, the LCR for ovarian cancer in these pa-
tients is also significantly higher and may reach 60 % by
70 years of age [5]. The BRCA2 gene, when altered, is
responsible for approximately 30 to 40 % of all cases of
hereditary breast cancer. The LCR for breast cancer in
women harboring germline mutations in this gene is
similar to the risk of carriers of germline mutations in
BRCA1 (44 to 68 % until 70 years of age), whereas the
risk of ovarian cancer ranges from 11 to 40 % [5–8].
Families with mutations in BRCA1/2 differ in terms of
age at diagnosis, the number of family members affected,
and tumor prognosis [9]. Currently, several reports in
the literature point to the role of polymorphisms as gen-
etic modifiers of the risk of cancer in families and as re-
sponsible factors for part of this diversity identified in
the families with known mutations [10–12].
In 2007, a large study was conducted by Easton and
collaborators [13] involving genome-wide association
studies (GWAS) of 4,398 cases (women with breast cancer)
and 4,316 controls, followed by a validation step involving
21,860 cases and 22,578 controls. This study identified sin-
gle nucleotide polymorphisms (SNPs) in five loci that were
associated with the risk of developing breast cancer: 1)
rs2981582 (C > T) in gene FGFR2, which encodes a tyro-
sine kinase receptor that acts in the development of the
mammary glands; 2) rs3803662 (C > T), localized in a re-
gion that includes TNRC9; 3) rs889312 (A >C), localized
in a region that includes MAP3K1 in addition to two puta-
tive genes, MGC33648 and MIER3; 4) rs3817198 (T >C)
in gene LSP1; and 5) rs13281615 (A >G), which resides in
a region that does not include any known gene (8q24) but
where variants associated with an increased risk of prostate
and colorectal cancer have been identified. The authors
correlated the presence of the above mentioned polymor-
phisms with histopathological characteristics such as posi-
tivity or negativity for the estrogen and progesterone
hormone receptors, stage of tumor development, nodes,
size, histology and stage at diagnosis. Among the five
SNPs mentioned above, three (rs2981582, rs3803662 and
rs889312) were significantly associated with an increased
risk of breast cancer in estrogen receptor-positive indi-
viduals. Women who were TT homozygous in SNP
rs3803662 and who had estrogen-negative tumors exhib-
ited a risk of developing breast cancer that was 1.28-fold
(95 % CI = 1.13–1.45) higher than women who were
homozygous for the wild-type allele (present in 53 % of
the controls). Besides, Hunter and colleagues [14] identi-
fied an association between the SNP rs2981582 and in-
creased risk for breast cancer among postmenopausal
white women in a study involving 1,145 cases of invasive
breast cancer and 1,142 controls. This association was fur-
ther validated in 1,176 cases and 2,072 controls from three
additional studies.
Studies involving rs3817198 have found that the least
frequent allele (C) leads to an increase of approximately
10 % in the risk of breast cancer in Caucasian women;
however, the same allele has a protective effect among
women of African ascent [15, 16].
Considering the factors described above and the pos-
sible modifying effect conferred by polymorphisms, the
objective of this study was to evaluate the frequency of
the polymorphisms rs2981582, rs3803662, rs889312,
rs3817198, and rs13281615 in women with breast can-
cer, with or without mutations in the BRCA1 and
BRCA2 genes, and to correlate the frequency of the dif-
ferent polymorphisms with the family history of cancer
in general and, more specifically with the history of
breast and ovarian cancer and with the histopathological
features of the tumors.
Materials and Methods
Cases
This project was approved by the Research Ethics Com-
mittee of the Barretos Cancer Hospital. All the partici-
pants in the study were treated at this institution and
signed an informed consent form. The women from the
oncogenetics department underwent genetic testing for
mutations in the BRCA1 and BRCA2 genes and, based
on the results, were allocated to three different groups:
a) Group 1: 51 women with a personal and family his-
tory of breast cancer with a pathogenic germline muta-
tion in the BRCA1 and/or BRCA2 genes; b) Group 2: 53
women with a personal and family history of breast can-
cer with the presence of a variant of unknown clinical
significance (VUS) identified in the BRCA1 and/or
BRCA2 genes; c) Group 3: 100 women with a personal
and family history of breast cancer without a pathogenic
mutation and/or mutation of unknown clinical signifi-
cance identified in the BRCA1 and/or BRCA2 genes.
Molecular Analysis
For the polymorphism analysis, DNA was extracted
using the QIAamp Blood DNA Mini-Kit (Qiagen) ac-
cording to the manufacturer's instructions. Genotyping
was performed through PCR amplification using the
Hot Start Taq enzyme (Qiagen). Following amplifica-
tion, the products were purified with the ExoSap en-
zyme (USB products) and sequenced bidirectionally
using the BigDye Terminator v3.1 Kit (Applied
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Biosystems, USA). Electrophoresis was run in the au-
tomated sequencer model 3500 (Applied Biosystems,
USA).
For the analysis of mutations in the BRCA1 and
BRCA2 genes and the subsequent separation of the par-
ticipants into the three study groups, a multiplex PCR
amplification of all coding exons of the BRCA1 (NCBI;
NM_007294.3) and BRCA2 (NCBI; NM_000059.3) genes
and their respective flanking intronic regions was per-
formed, followed by bidirectional sequencing using two
platforms (ABI 3500 XL sequencer) and a new generation
sequencer (Ion Torrent PGM, Applied Biosystems). In
addition, large rearrangements were investigated using the
multiplex ligation-dependent probe amplification (MLPA)
technique.
Statistical Analysis
The program SPSS v.21.0 for Windows (Chicago, IL)
was used for the statistical analysis. The categorical vari-
ables were described using absolute frequencies and
relative percentage frequencies. The correlations were
obtained using the Chi-square and Fisher’s exact tests.
The level of significance adopted in all the tests was 5 %.
Results
Sequencing of BRCA1 and BRCA2 of all coding regions
was performed for the 204 patients. Fifty-one had a
pathogenic mutation identified (30 with BRCA1 muta-
tions and 21 with a germline pathogenic mutation on
BRCA2 gene), 53 had a VUS identified on BRCA1 and/
or BRCA2 genes and 100 women were tested negative
for both genes. All 204 women had a personal history of
breast cancer (mean age at diagnosis = 38.4 years). In
addition all participants had a positive family history of
cancer, suggestive of Hereditary Breast and Ovarian Cancer
Predisposition Syndrome (for details regarding criteria
used for genetic testing at Barretos Cancer Hospital see
Palmero et al., “Oncogenetics service and the Brazilian
public health system: the experience of a reference Cancer
Hospital”, manuscript accepted for publication in 2015
at Genetics and Molecular Biology journal). The main
histological tumor types were invasive ductal carcin-
omas (91.8 %) and lobular carcinomas (3.9 %). In
addition the great majority of the breast tumors (of the
probands) were grade II, T1/T2, N0 and M0. Details
about the family history of cancer and mutated gene can
be found in Additional file 1: Table S1.
The following polymorphisms were considered in this
study: rs2981582 in gene FGFR2 (allele frequency in the
general population: T: 0.404, C: 0.596), rs3803662 in
gene TNRC9 (allele frequency in the general population:
T: 0.440, C: 0.560), rs889312 in gene MAP3K1 (allele
frequency in the general population: C: 0.387, A: 0.613),
rs3817198 in gene LSP1 (allele frequency in the general
population: T: 0.785, C: 0.215) and rs13281615 at 8q24
(allele frequency in the general population: A: 0.509,
G: 0.491).
Table 1 presents the genotype frequency of the five
polymorphisms that were evaluated and their distribu-
tion in the different study groups.
Although there were no marked differences in the fre-
quency of the polymorphisms studied among the three
groups, some findings are noteworthy: i) there was a
higher frequency of TT homozygotes for rs3803662 in
the groups comprising women without mutations in the
BRCA1/BRCA2 genes; ii) regarding rs889312, an in-
crease was observed in the frequency of heterozygous
individuals among those without mutations or VUS in
BRCA1/2; and iii) the Group3 (WT) had a relatively in-
creased frequency of CC homozygotes for the SNP
rs3817198 compared to groups 1 and 2.
The analysis of the family history of cancer according
to the different polymorphisms studied is detailed in
Table 2.
Table 1 Frequency of polymorphisms rs3803662 (TNRC9),
rs2981582 (FGFR2), rs13281615, rs889312 (MAP3K1) and
rs3817198 (LSP1) per group
Variable Group 1 Group 2 Group 3
P valueaN (%) N (%) N (%)
rs3803662 (TNRC9) 0.027
TT 5 (9.8) 12 (22.6) 17 (17.3)
CT 27 (52.9) 24 (45.3) 47 (48.0)
CC 19 (37.3) 17 (32.1) 34 (34.7)
rs2981582 (FGFR2) 0.031
TT 14 (27.5) 9 (16.7) 26 (26.3)
CT 22 (43.1) 33 (61.1) 49 (49.5)
CC 15 (29.4) 12 (22.2) 24 (24.2)
rs13281615 (8q24) 0.029
AA 14 (27.5) 11 (20.4) 27 (27.0)
AG 24 (47.1) 26 (48.1) 48 (48.0)
GG 13 (25.5) 17 (31.5) 25 (25.0)
rs889312 (MAP3K1) 0.029
CC 8 (15.7) 8 (14.8) 11 (11.0)
CA 21 (41.2) 20 (37.0) 55 (55.0)
AA 22 (43.1) 26 (48.1) 34 (34.0)
rs3817198 (LSP1) 0.023
TT 26 (51.0) 28 (51.9) 44 (44.4)
TC 22 (43.1) 24 (44.4) 43 (43.4)
CC 3 (5.9) 2 (3.7) 12 (12.1)
Group 1: women with germline mutations in the BRCA1/BRCA2 genes; Group 2:
women with VUS in the BRCA1/BRCA2 genes; Group 3: women WT for the
BRCA1/BRCA2 genes; Group 4: control, sporadic group
Values in bold indicate statistical significance (p < 0.05)
aChi-square
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Number of generations with cancer Number of breast
cancer cases
Polymorphism ≤3 >3 Yes No Yes No 1 2 3 4 ≤3 >3
rs3803662 – TT 13 21 4 30 4 30 8 17 8 1 25 9
N (%) (20.0) (15.3) (20.0) (16.5) (14.3) (17.2) (22.2) (17.9) (12.5) (16.7) (17.6) (15.3)
rs3803662 - TC 25 73 9 89 15 83 15 44 35 4 63 34
N (%) (38.5) (53.3) (45.0) (48.9) (53.6) (47.7) (41.7) (46.3) (54.7) (66.7) (44.4) (57.6)
rs3803662 - CC 27 43 7 63 9 61 13 34 21 1 54 16
N (%) (41.5) (31.4) (35.0) (34.6) (32.1) (35.1) (36.1) (35.8) (32.8) (16.7) (38.0) (27.1)
Total N (%) 65 (100.0) 137 (100.0) 20 (100.0) 182 (100) 28 (100) 245 (100.0) 36 (100) 95 (100) 64 (100) 6 (100) 142 (100) 59 (100)
P valuea (p = 0.602) (p = 0.849) (p = 0.998) (p = 0.890) (p = 0.429)
rs2981582 - TT 17 32 4 45 2 47 6 28 12 3 33 15
N (%) (25.8) (23.2) (20.0) (24.5) (7.5) (26.6) (10.7) (29,5) (18,2) (50,0) (23,1) (25,0)
rs2981582 - TC 28 76 13 91 18 86 16 44 42 1 70 34
N (%) (42.4) (55.1) (65.0) (49.5) (66.6) (48.6) (44.4) (46.3) (63.6) (16.7) (59.0) (56.7)
rs2981582 - CC 21 30 3 48 7 44 14 23 12 2 40 11
N (%) (31.8) (21.7) (15.0) (26.1) (25.9) (24.9) (38.9) (24,2) (18.2) (33.3) (28.0) (18.3)
Total N (%) 120 156 20 184 27 177 36 95 66 6 143 60
(100.0) (100) (100.0) (100) (100) (100.0) (100) (100) (100) (100) (100) (100)
P valuea (p = 0.475) (p = 0.688) (p = 0.163) (p = 0.172) (p = 0.283)
rs13281615 - AA 21 31 3 49 11 41 14 22 16 0 37 15
N (%) (31.8) (22.3) (15.0) (26.5) (39.3) (23.2) (38.9) (23.2) (23.9) (0.0) (25.7) (25.0)
rs13281615 - AG 37 61 5 93 12 86 16 51 27 3 70 27
N (%) (56.1) (43.9) (25.0) (50.3) (42.8) (48.6) (44.4) (53.7) (40.3) (50.0) (48.6) (45.0)
rs13281615 -GG 8 47 12 43 5 50 6 22 24 3 37 18
N (%) (12.1) (33.8) (60.0) (23.2) (17.9) (28.2) (16.7) (23,2) (35.8) (50.0) (25.7) (30.0)
Total N (%) 66 139 20 185 28 177 36 95 67 6 144 60
(100) (100) (100.0) (100) (100) (100) (100) (100) (100) (100) (100) (100)
P valuea 0.004 0.005 0.072 0.007 0.654
N (%) (16.7) (11.5) (25.0) (11.9) (7.1) (14.1) (11.1) (14.7) (13.4) (0.0) (14.6) (10.0)
rs889312 - CA 28 68 12 84 12 84 18 36 36 5 66 30
N (%) (42.4) (48.9) (60.0) (45.4) (42.9) (47.5) (50.0) (37.9) (53.7) (83.3) (45.8) (50.0)
rs889312 - AA 27 55 3 79 14 68 14 45 22 1 57 24
N (%) (40.9) (39.6) (15.0) (42.7) (50.0) (38.4) (38.9) (47.4) (32.8) (16.7) (39.6) (40.0)
Total N (%) 66 (100) 139 20 185 28 177 36 95 67 6 144 60
(100) (100) (100) (100) (100) (100) (100) (100) (100) (100) (100)
P valuea 0.707 0.011 0.179 0.373 0.632
rs3817198 - TT 31 67 6 92 18 80 21 41 33 2 70 28
N (%) (47.0) (48.6) (30.0) (50.0) (66.7) (45.2) (58.3) (43.2) (50.0) (33.3) (49.0) (46.7)
rs3817198 - TC 25 64 10 79 6 83 13 48 24 4 61 28
N (%) (37.9) (46.4) (50.0) (42.9) (22.2) (46.9) (36.1) (50.5) (36.4) (66.7) (42.7) (46.7)
rs3817198 - CC 10 7 4 13 3 14 2 6 9 0 12 4
N (%) (15.2) (5.1) (20.0) (7.1) (11.1) (7.9) (5.6) (6.3) (13.6) (0.0) (8.4) (6.6)
Total N (%) 66 138 20 184 27 177 36 95 66 6 143 60
(100) (100) (100) (100) (100) (100) (100) (100) (100) (100) (100) (100)
P valuea 0.223 0.029 0.166 0.275 0.954
Values in bold indicate statistical significance (p < 0.05)
aChi-square
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When comparing the genotypes with the family history
of cancer, some potential associations were identified, in-
cluding the occurrence of bilateral breast cancer and
homozygosity for the G allele in rs13281615 and “C” in
rs889312 in which 85 % of women with bilateral breast
cancer had at least one C allele (or G allele in the case
of rs13281615). Likewise, 85 % of the women with bilat-
eral breast cancer had at least one T allele in rs2981582.
Furthermore, regarding allele G in rs13281615, we ob-
served that the proportion of individuals who were
homozygous for this allele increased with the number of
generations affected by cancer. Moreover, we observed
that in the case of rs3803662 and rs2981582, heterozy-
gous TC individuals presented a higher number of can-
cer cases (in general) and a higher number of breast
cancer cases.
Detailed data on the frequency of the different geno-
types versus the family history of cancer with the women
subgrouped according to their BRCA1 and BRCA2 gene
mutation status are found in Additional file 1: Table S2
to S6.
In addition, the frequency of the different genotypes
was compared to the family history by separately consid-
ering the women with a mutation in BRCA1 to those
with mutations in BRCA2. Given the limited sample size
of patients with a deleterious mutation identified in
these genes, the group stratification per mutated gene
limited the statistical analyses that were conducted.
However, some trends could be observed, for example,
all of the women with mutations in the BRCA2 gene
with bilateral breast cancer were homozygous for the G
allele in rs132281615, and among those with mutations
in BRCA1 and with bilateral breast cancer, 86 % had at
least one G allele. Moreover, in regard to rs3817198, all
of the women with mutations in BRCA1 and with ovar-
ian cancer had at least one T allele (with 88.9 % being
TT homozygotes); however, the same pattern was not
observed for the women with mutations in BRCA2 and
a personal history of ovarian cancer (p = 0.006). To reach
a conclusion on the association of these polymorphisms
with the BRCA1/2 mutational status and with a family
history of cancer, more patients with these characteris-
tics must be genotyped.
The data correlating the genotypes of the five poly-
morphisms that were analyzed with the status of the
hormone receptors (estrogen, progesterone and HER2)
are shown in Table 3.
When the different polymorphisms were analyzed with
the hormone receptors, we observed an increased fre-
quency of heterozygotes for rs3803662 in individuals
with estrogen receptor (ER)-positive tumors, in individ-
uals with progesterone receptor (PR)- positive tumors
and in individuals who were negative for the HER2 re-
ceptor. Regarding rs2981582, individuals with at least
one T allele more frequently exhibited positivity for the
three receptors (ER, PR and HER2). We also observed
an increased frequency of the WT allele among ER-
negative individuals. For the SNPs rs13281615, rs889312
and rs3817198, no association was found between their
frequencies and the hormone receptors considered.
When the analysis of the polymorphisms with the hor-
mone receptors was conducted separately for the groups
studied (Additional file 1: Table S6 to S10), we noted
some associations. Regarding the SNP rs2981582 in gene
FGFR2, we observed an association between group 2
(with VUS in the BRCA1/2 genes) with the ER in which
the presence of TT homozygotes was not observed, and
TC heterozygosity was present in 73.7 % of the ER- nega-
tive cases (Additional file 1: Table S8). Additionally, when
this analysis was performed for the SNP rs13281615, we
observed an association with HER-2 positivity in group 3
(WT for BRCA1/2), with 50 % of individuals being AG
heterozygotes vs. 25 % and 28.6 % of those from groups
one and two respectively (Additional file 1: Table S9). For
the SNP rs889312 in gene MAP3K1, an association with
HER-2-negative tumors was observed in group 2, and
46.0 % of the negative cases were homozygous for the A
allele (Additional file 1: Table S10). The SNP rs3817198
in gene LSP1 showed an association with the ER in
group 3 (WT), in which 50.0 % of the ER-positive cases
were heterozygous (TC) (Additional file 1: Table S11).
Finally, in the case of the SNP rs3803662 in gene
TNRC9, the increased frequency of allele C homozygos-
ity was more evident in groups 1 and 3, in which most
cases of ER-negative tumors have the CC genotype
(Additional file 1: Table S7).
An analysis of genotypes versus hormone receptors
was conducted by separately considering the individuals
with BRCA1 mutations and those with identified muta-
tions in BRCA2, but no association was observed in this
analysis (data not shown).
The association between the genotypes in the five
SNPs considered and the age at diagnosis was evaluated.
Although no significant association was identified, these
data are shown in Additional file 1: Table S12.
Discussion
Genetic polymorphisms are being widely evaluated as
modifiers of the genetic risk of disease by several re-
search groups. A study conducted by Garcia-Closas and
collaborators [17] evaluated the frequency of five poly-
morphisms that were previously reported to be associ-
ated with an increased risk of breast cancer [13] and
investigated whether the association between these poly-
morphisms and the risk of breast cancer was somehow
influenced by clinically relevant tumoral features in
23,039 cases of invasive breast cancer and in 26,273 con-
trols from 20 different studies. The authors found that
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common genetic variants (polymorphisms) influenced
the pathological tumor subtype, which provided add-
itional evidence of the biologically distinct behavior of
ER-positive versus ER- negative tumors.
In this study, we compared the genotype distribution
of the five polymorphisms that were previously reported
in the literature to be associated with the risk of breast
cancer [13, 17, 18] in three groups of women: women
at-risk for hereditary breast cancer, with germline muta-
tions in the BRCA1 and BRCA2 genes, women with VUS
identified in one of those genes, and women WT for
both genes. The genotype data from the five polymor-
phisms were then correlated with the family history of
cancer and the histopathological features of the tumors,
always considering a possible influence of the mutational
status of BRCA1/2. A similar work was performed by
Antoniou and collaborators in 2008,[19] where they
genotyped FGFR2 (rs2981582), TNRC9 (rs3803662), and
MAP3K1 (rs889312) SNPs in a sample of 10,358 muta-
tion carriers from 23 studies.
When we compared the genotypes of the polymor-
phisms analyzed with the pathological characteristics of
the tumors, we noted that, in the case of the SNP
rs3803662 in gene TNRC9, there was an increased fre-
quency of CC homozygotes among ER-negative individ-
uals (as previously reported by Easton and collaborators
[13] in 2007), and although the difference was not statis-
tically significant, it was possible to observe that this dif-
ference was stronger among women in groups 1 (with
mutations) and 3 (WT). Regarding the SNP rs2981582,
which was localized in gene FGFR2, we observed an in-
creased frequency of the T allele in women who were posi-
tive for the estrogen and progesterone receptors (p = 0.020
and p = 0.014, respectively); this increase in frequency
Table 3 Correlation between the genotype frequencies of the polymorphisms and the hormone receptors (overall)
Estrogen Progesterone Her-2
Polymorphisms Negative Positive Negative Positive Negative Positive Inconclusive
rs3803662 - TT N (%) 13 (16.5) 20 (18.0) 16 (18.0) 17 (16.5) 23 (16.9) 7 (14.9) 3 (100.0)
rs3803662 - TC N (%) 33 (41.8) 56 (50.5) 51 (41.8) 38 (42,7) 66 (48.5) 21 (44.7) 0 (0.0)
rs3803662 – CC N (%) 33 (41.8) 35 (31.5) 46 (37.7) 35 (39.3) 47 (34.6) 19 (40.4) 0 (0.0)
Total 79 (100.0) 111 (100.0) 122 (100.0) 89 (100.0) 136 (100.0) 47 (100.0) 3 (100.0)
P valuea 0.257 0.504 0.469
rs2981582 – TT N (%) 15 (219.2) 31 (27.2) 16 (18.0) 30 (28.6) 33 (23.9) 21 (25.5) 1 (33.4)
rs2981582 – TC 38 (48.7) 60 (52.6) 47 (52.8) 52 (49.5) 65 (47.1) 28 (59.6) 2 (66.6)
N (%)
rs2981582 – CC 25 (32.1) 23 (20.2) 26 (29.2) 23 (21.9) 40 (29.0) 7 (14.9) 0 (0.0)
N (%)
Total 78 (100.0) 114 (100.0) 89 (100.0) 105 (100.0) 138 (100.0) 47 (100.0) 3 (100.0)
P valuea 0.054 0.076 0.120
rs13281615 - AA N (%) 20 (25.3) 30 (26.3) 26 (28.9) 25 (23.8) 32 (23.2) 14 (29.2) 2 (66.6)
rs13281615 - AG N (%) 35 (44.3) 56 (49.1) 40 (44.4) 51 (48.6) 68 (49.3) 20 (41.7) 1 (33.4)
rs13281615 - GG N (%) 24 (30.4) 28 (24.6) 24 (26.7) 29 (27.6) 38 (27.5) 14 (29.2) 0 (0.0)
Total 79 (100.0) 114 (100.0) 90 (100.0) 105 (100.0) 138 (100.0) 48 (100.0) 3 (100.0)
P valuea 0.523 0.566 0.291
rs889312 - CC N (%) 12 (15.2) 15 (13.2) 10 (11,1) 17 (16.2) 21 (15.2) 5 (10.4) 0 (0.0)
rs889312 - CA N (%) 35 (44.3) 54 (47.4) 45 (50.0) 45 (42.9) 61 (44.2) 25 (52.1) 1 (33.3)
rs889312 - AA N (%) 32 (40.5) 45 (39.5) 35 (38.9) 43 (41.0) 56 (40.6) 18 (37.5) 2 (66.7)
Total 79 (100.0) 114 (100.0) 90 (100.0) 105 (100.0) 138 (100.0) 48 (100.0) 3 (100.0)
P valuea 0.921 0.760 0.554
rs3817198 - TT N (%) 42 (53.8) 51 (44.7) 49 (55.1) 45 (42,9) 68 (49.3) 21 (44.7) 0 (0.0)
rs3817198 - TC N (%) 31 (39,7) 54 (47.4) 34 (38.2) 52 (49,5) 59 (42.8) 23 (48.9) 3 (100)
rs3817198 - CC N (%) 5 (6.4) 9 (7.9) 6 (6.7) 8 (7.6) 11 (8.0) 3 (6.4) 0 (0.0)
Total 78 (100.0) 114 (100.0) 89 (100.0) 105 (100.0) 138 (100.0) 47 (100.0) 3 (100.0)
P valuea 0.248 0.145 0.449
Values in bold indicate statistical significance (p < 0.05)
aChi-square
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among individuals positive for the hormone receptors (ER
and PR) did not depend on the group to which the women
belonged. The same association with the rs2981582 and
positivity for estrogen and progesterone receptors was de-
scribed by Garcia-Closas and collaborators in an analysis
of the association among breast cancer risk, FGFR2
rs2981582 and clinical and pathological characteristics
and they found that the effect of rs2981582 was stronger
in ER/PR-positive patients [17]. Additionally, Liang and
colleagues [20] in a work involving 1049 breast cancer
Chinese patients and 1073 cancer-free controls found the
same association. The authors stated that this association
possibly can be due to the interaction of FGFR2 variants
with high levels of endogenous sex hormones (FGFR2 is
upregulated in ERα-positive breast tumors) [21], especially
estrogens, which may increase breast cancer risk.
There are several studies evaluating the effects of poly-
morphisms on the risk of cancer and their association
with tumor features. According to the study published
by Tapper and collaborators [22] in 2008, some poly-
morphisms capable of altering the risk of breast cancer
are being discovered. The study conducted by the above
mentioned authors had the objective of evaluating how
those variants may influence the prognosis and risk of
developing breast cancer. For this purpose, 1,001 women
with non-familial, invasive breast cancer that was diag-
nosed at early age were analyzed compared to a group of
women with hereditary breast cancer; the presence and
frequency of 206 SNPs in 30 candidate genes were eval-
uated in the two groups. An association with an in-
creased risk of developing breast cancer was found in
the SNPs localized in the CASP8, TNRC9 and ESR1
genes. The authors also reported an association between
survival and eight SNPs in six genes (MAP3K1, DAPK1,
LSP1, MMP7, TOX3 and ESR1) and another SNP in a
gene-free region in 8q24. For the SNPs in genes MMP7,
TOX3 and MAP3K1, the survival effects did not depend
on the known main clinical prognosis factors. The effect
of the SNP in ESR1 on survival was more significant
when only ER-positive tumors were evaluated. When the
cases were stratified according to tumor features, it was
observed that the SNPs in FGFR2 and TOX3 were asso-
ciated with the disease. Finally, the study showed that
several SNPs were associated with survival. In some
cases, this association may occur because of an effect on
the tumor characteristics that has an impact on progno-
sis; in other cases, the effect appears to be independent
of these prognostic factors [22].
Results published by Fanale and collaborators [11] in
2012 demonstrated the association of some SNPs with
breast cancer. The genes in which the polymorphisms
described reside in are TNRC9, FGFR2, MAP3K1, H19
and LSP1. The most strongly associated SNP is localized
in gene FGFR2, which was overexpressed in 5-10 % of
the cases of breast cancer. The SNP in gene TNRC9
showed a stronger association with breast cancer and
appeared to be correlated with the presence of bone me-
tastases and positivity for the estrogen receptor. The
SNP rs889312 in gene MAP3K1 showed sensitivity only
in individuals harboring mutations in BRCA2, and it was
not associated with an increased risk in carriers of
BRCA1 mutations. Several SNPs in LSP1 and H19 were
most likely associated with the risk of developing cancer.
Therefore, the study concluded that the identification of
risk-modifying polymorphisms may lead to a better un-
derstanding of the biological mechanism of breast can-
cer, thus improving the prevention, detection and early
treatment of the disease.
The results of the analyses of the presence and fre-
quency of the five polymorphisms considered here were
compared to the family history of cancer. Several associa-
tions were identified in that comparison, either with the
number of cancer cases in the family (associated with the
SNPs rs2981582 and rs13281615), with the presence of bi-
lateral breast cancer (SNP rs13281615) or with the num-
ber of generations affected by cancer (SNP rs13281615).
Moreover, regarding allele G of rs13281615, we observed
that the proportion of individuals who were homozygous
for this allele increased as the number of generations af-
fected by cancer increased. Many of the findings described
here corroborate data in the literature, such as the associ-
ation found between SNP rs13281615 and a positive fam-
ily history of cancer, which was a correlation previously
reported by Gorodnova and collaborators in 2010 [23].
Besides, Gong et al. [24] published a meta-analysis that
included 14 studies involving 44,283 cases and 55,756
controls found that the GG and G-allele genotypes of
rs13281615 at 8q24 are significantly associated with in-
creased risk for breast cancer
The effect of polymorphisms on the family history of
cancer was also reported by Huijts and collaborators
[25], who showed an association between rs2981582 in
gene FGFR2 and the average number of first- and
second-degree relatives with breast and/or ovarian can-
cers (P = 0.05). The authors also found an association
with the age at diagnosis, in which individuals who were
heterozygous or homozygous for the least frequent allele
for rs3803662 had a higher probability of having the
cancer diagnosed at an age younger than 60 years.
An association with age at diagnosis was not observed
in this study for any of the five polymorphisms consid-
ered. However, we should reinforce that these findings
should be regarded with caution, given the relatively
small size of our study, which is the main limitation of
our study. For that reason the obtained data and the
possible associations identified with the tumor patho-
logical features and with the family history of cancer must
be validated using a larger sample size. Nonetheless, if
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these associations are confirmed, we will have additional
data to understand the epidemiology of hereditary and fa-
milial cancer in our population. In addition, the results
contributed to the continued research efforts in the search
for common variants for breast cancer that could help to
explain the high variability observed among family history
of families with hereditary susceptibility to breast cancer.
Thus, although no significant association between the
presence of the 5 analyzed polymorphisms and the oc-
currence of pathogenic mutation in BRCA1/BRCA2 has
been identified, the influence of polymorphisms acting
as genetic modifiers of cancer was observed, especially
for the SNP rs13281615 whose presence the G allele was
associated with the occurrence of bilateral breast cancer,
as well as with an increased number of cancer cases in
the family and with an increasing number of generations
affected by cancer and, this association was, in general,
independent of the mutational status of the BRCA1 or
BRCA2 genes.
Conclusion
Some potential associations were found between the five
polymorphisms analyzed in this study previously re-
ported in the literature as being associated and an in-
crease in the risk of breast cancer, with an emphasis
placed on the effect of these polymorphisms on the fam-
ily history of cancer and on hormone receptor positivity/
negativity. These findings must be interpreted with cau-
tion because of the limited sample size in this study. The
data must be validated with a larger number of cases
and, if confirmed, the clinical relevance of the associa-
tions identified and their applicability in medical practice
must be considered carefully. However, the results pre-
sented here provide interesting information on the
modifying effect of polymorphisms on the family history
of cancer and may be a variable to consider in the ana-
lysis of tumor diversity, and of the family history ob-
served in families with hereditary breast cancer (even in
those harboring the same type of genetic alteration).
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